Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125642 · ClinicalTrials.gov registry record · Phase 2
Auto Stem Cell Transplant for Lymphoma Patients
A Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03125642 is a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 150 participants, roughly in line with the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT03125642, a Phase 2 study of Non-Hodgkin Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Etoposide
- DRUG BCNU
- DRUG AraC
- PROCEDURE Peripheral blood stem cell transplantation
Study Locations (1)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2017-04-20 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125642
The ClinicalTrials.gov registry entry for NCT03125642 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 150-participant average among 104 other Non-Hodgkin Lymphoma trials with a reported enrollment target. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT03125642 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03125642 about?
NCT03125642 is a clinical study titled "Auto Stem Cell Transplant for Lymphoma Patients". This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
What is the current status of trial NCT03125642?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2017-04-20. Estimated completion is 2027-04-30.
What conditions does trial NCT03125642 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Hodgkin Lymphoma.
What interventions are being tested in trial NCT03125642?
The interventions under investigation include: Melphalan (DRUG), Etoposide (DRUG), BCNU (DRUG), AraC (DRUG), Peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT03125642?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03125642 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.